We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Australians pay some of the lowest medicine prices in the world for a reason: our Pharmaceutical Benefits Scheme. Here’s how ...

Merck & Co. is making waves as an undervalued S&P 500 stock, boasting a forward P/E ratio of 10.52 and strong hedge fund ...

“Due to significant reductions in demand for these products, the company has decided to cease operations at the plant,” the ...

The general mood among these heavyweight investors is divided, with 63% leaning bullish and 36% bearish. Among these notable ...

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look ...

Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology.

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...

Merck & Co Inc. has become a top contender for the most profitable value stock, but it faces some challenges. Merck boasts a forward P/E ratio of 10.36 and TTM net income of $17.117 billion. Despite ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...